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> 75 years, a Karnofsky performance score of < 70, an altered 
mentation and a creatinine clearance of > 90 ml/min were sig-
nificantly associated with an inferior outcome. On multivari-
ate analysis, only increased creatinine clearance and altered 
mentation remained significant. 
Although the authors discuss various approaches for inter-
preting their data, it seems inescapable to conclude that high 
creatinine clearance (reflecting intact renal function) could 
only be a negative prognostic factor, because these patients 
were underdosed with methotrexate. The treatment regimen 
that they employed has the major weakness that it does 
not take renal function into account. By contrast, in the 
G-PCNSL-SG-1 trial, the methotrexate dose was governed by 
the glomerular filtration rate [1], and we had shown previ-
ously that this is definitely feasible in elderly patients with 
PCNSL [6]. Although only very few of the patients studied by 
Lee et al. appeared to have received whole brain radiotherapy 
at progression, the authors reported that they did not observe 
any delayed neurotoxicity. This is a surprising finding, given 
that they also used intrathecal chemotherapy; however, the 
 information on how this was assessed was sparse.
In general, it may be that a cut-off age of 60 to define 
 elderly or frail patients is not fully adequate and more inten-
sive regimens with a full methotrexate dose are probably 
 warranted in most patients at least until the age of 70. For 
 future trials, the necessary age cut-off should probably be 
 supplemented with frailty scores to avoid undertreatment of 
elderly patients who are able to tolerate standard high-dose 
methotrexate chemotherapy.
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Higher age has consistently been identified as a negative 
prognostic factor in patients with primary central nervous 
 system lymphoma (PCNSL). The inferior outcome in the el-
derly has often been attributed to less intensive treatment 
being administered, but beyond that, there seems to be a 
 fundamental difference in the response to – or benefit from – 
treatment in the elderly. In the G-PCNSL-SG-1 trial [1], 
126 of 526 eligible patients were aged 70 or older. Their over-
all response rate was only mildly lower than in the younger 
patients, with 44% as opposed to 57% (p = 0.016). The most 
notable difference, which accounted for the overall inferior 
outcome, was the duration of progression-free life in patients 
achieving a complete response: it was 35 months in the 
younger patients compared to 16.1 months in the elderly 
(p = 0.024). Less intensive treatment at recurrence may fur-
ther contribute to the poorer outcome [2]. The biological basis 
for early recurrence after complete responses in the elderly 
remains obscure, but may involve host rather than tumor 
factors.
In the present issue of Oncology Research and Treat-
ment, Lee and colleagues from Japan report on ‘Prognosis 
 factors in Japanese elderly patients with primary CNS lym-
phoma treated with non-radiation, intermediate-dose metho-
trexate-containing regimen’ [3]. This is an extension of a 
 previously published series [4]. The authors adopted the cur-
rent trend of omitting whole brain radiotherapy from the 
 primary treatment of these patients [5], and treated their pa-
tients with an ‘intermediate dose’ methotrexate-based regi-
men containing 1 g/m2 intravenous (i.v.) methotrexate on 
days 1, 10, and 20, 40 mg/m2 i.v. ranimustine on day 1, 60 mg/m2 
oral procarbacine from days 1 to 7, and i.v. or oral methyl-
prednisolone at a dose of 120 mg/m2 every other day from 
days 1 to 20 and then at a dose of 60 mg/m2 from days 21 to 45. 
Further, 15 mg methotrexate and 40 mg cytarabine were given 
intrathecally on days 1, 5, 10 and 15. This was followed by a 
similarly designed maintenance therapy. Using this regimen, 
progression-free survival and overall survival rates at 3 years 
were 29.8% and 56.2%. On univariate analysis, an age of 
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